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Abstract
Introduction Because CYP17  can influence the degree of
exposure of breast tissues to oestrogen, the interaction between
polymorphisms in this gene and hormonal risk factors is of
particular interest. We attempted to replicate the findings of
studies assessing such interactions with the -34T→ C
polymorphism.
Methods Risk factor and CYP17 genotyping data were derived
from a large Australian population-based case-control-family
study of 1,284 breast cancer cases and 679 controls. Crude
and adjusted odds ratio (OR) estimates and 95% confidence
intervals (CIs) were calculated by unconditional logistic
regression analyses.
Results We found no associations between the CYP17
genotype and breast cancer overall. Premenopausal controls
with A2/A2 genotype had a later age at menarche (P < 0.01).
The only associations near statistical significance were that
postmenopausal women with A1/A1 (wild-type) genotype had an
increased risk of breast cancer if they had ever used hormone
replacement therapy (OR 2.40, 95% CI 1.0 to 5.7; P = 0.05)
and if they had menopause after age 47 years (OR 2.59, 95%
CI 1.0 to 7.0; P = 0.06). We found no associations in common
with any other studies, and no evidence for interactions.
Conclusion We observed no evidence of effect modification of
reproductive risk factors by CYP17  genotype, although the
experiment did not have sufficient statistical power to detect
small main effects and modest effects in subgroups.
Associations found only in subgroup analyses based on
relatively small numbers require cautious interpretation without
confirmation by other studies. This emphasizes the need for
replication in multiple and large population-based studies to
provide convincing evidence for gene–environment interactions.
Introduction
The association between exposure to endogenous and exog-
enous steroid hormones and breast cancer risk is well estab-
lished [1]. Consequently, genetic polymorphisms in genes
involved with hormone-metabolizing pathways have been
widely studied for evidence of their contribution to breast can-
cer risk [2,3]. One such candidate gene is CYP17 on chromo-
some 10q24.3, which encodes the enzyme cytochrome
P450c17α  (17α -hydroxylase; 17/20 lyase). P450c17α  func-
tions at two different points in the steroid biosynthesis path-
way; the 17α  hydroxylase activity can convert progesterone to
17α -hydroxyprogesterone, and the 17/20 lyase function may
further convert 17α -hydroxyprogesterone to androstenedione
(the precursor of both oestrone and testosterone) [4].
ABCFS = Australian Breast Cancer Family Study; CI = confidence interval; HRT = hormone replacement therapy; OR = odds ratio; PCR = polymer-
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One common polymorphism in CYP17 has been extensively
studied [5-23]. It is a T→ C nucleotide substitution 34 base
pairs upstream of the translation initiation site in the 5' pro-
moter region. A subset of the literature refers to the wild-type
T allele as A1, and the variant C allele as A2. The C allele cre-
ates an additional Sp1-type (CCACC box) promoter site, and
although it was initially suggested to increase expression of
the gene [9], a subsequent study did not observe binding to
the human transcription factor Sp-1 [16]. There is conflicting
evidence indicating that the CYP17 -34T→ C polymorphism
might influence endogenous steroid hormone levels [11,24-
31], and the CC genotype has also been reported to be asso-
ciated with the relative abundance of the 2OHE and 16α  OHE
forms of oestrogen [32]. A recent study also found the poly-
morphism associated with higher levels of DHEAS in premen-
opausal women and higher levels of oestradiol in
postmenopausal women [33].
Although a few studies have found evidence for an association
between this polymorphism and risk of breast cancer
[7,9,19,23], these positive associations were observed for
specific subgroups of cases defined by tumour aggressive-
ness, age at onset, or family history of breast cancer. Two
recent meta-analyses [3,34] showed no overall association of
breast cancer with the C (A2) variant, when comparing allele
frequencies, or genotypes defined by these alleles under a
dominant or recessive model. Results were consistently null in
different ethnic groups [34].
As CYP17 may influence the degree of exposure of breast epi-
thelial cells to oestrogen, the possibility that the effects of dif-
ferent hormonal risk factors is dependent on different CYP17
genotype is of particular interest. Some studies have sug-
gested that CYP17 genotype is associated with hormonal risk
factors, and/or that the association between breast cancer
and hormonal risk factors depends on CYP17 genotypes. That
is, CYP17 genotype may be an effect modifier. The hormonal
risk factors examined in this manner have included age at
menarche, age at first birth, use of oral contraceptives, age at
menopause, and hormonal replacement therapy. So far, stud-
ies examining these gene–environment interactions or effect
modifications have generally been small and have reported
conflicting results [5,8,9,12,13,15,18,19,21,22,27,35-37].
For example, the CYP17 variant was significantly associated
with earlier age at menarche in only two of eight reports, and
an effect of later age at menarche (at least 13 years) limited to
women with the wild-type T (A1) homozygous genotype was
evident in only 4 of 11 reports. Moreover, as alluded to in a
recent review of studies of the CYP17 polymorphisms and
hormone levels [38], the published literature is compromised
because many reported 'associations' were not statistically
significant, and the possibility of publication bias in selective
reporting of such data cannot be excluded.
We previously published Australian data on the overall rela-
tionship between this CYP17 genetic polymorphism and the
risk of breast cancer before the age of 40 years [23]. In the
present study of a larger sample of women under 60 years, we
considered the issue of effect modification. We studied repro-
ductive and hormone-related factors previously documented
to be putative effect modifiers [5,9,11,19,24,35]. We used the
same categorization as in the Western New York Breast Can-
cer Study (WNYBCS) [5], the most comprehensive study
assessing CYP17 genotype as a potential effect modifier, in
an attempt to replicate findings with an independent data set.
Materials and methods
Subjects
The Australian Breast Cancer Family Study (ABCFS) is a pop-
ulation-based case-control-family study of breast cancer
before the age of 60 years [39-41]. Sampling of cases was
stratified by age at onset, and half were diagnosed before age
40 years, so the study is predominantly of premenopausal
women. Cases were women living in Melbourne or Sydney
diagnosed with a first primary breast cancer, identified through
the Victoria and New South Wales cancer registries. Controls
were women with no previous breast cancer selected from the
electoral roll (adult registration for voting is compulsory in Aus-
tralia) by a stratified random sampling, frequency-matched for
age. Questionnaires used to measure exposure to risk factors
and family cancer history have been described previously
[23,40,41]. Ethical approvals for the ABCFS and this genotyp-
ing study were obtained from The University of Melbourne, the
Cancer Councils of Victoria and New South Wales, and the
Queensland Institute of Medical Research.
For the purpose of these analyses, subjects were restricted to
the women who identified themselves as being white/Cauca-
sian (details in [23]). Molecular analyses (see [41]) have so far
identified 41 Caucasian cases carrying a deleterious germline
mutation in either BRCA1 or BRCA2, and these subjects have
been excluded from the analyses.
Molecular analysis
As described in detail previously [23], the CYP17 -34T→ C
polymorphism was measured in DNA extracted from cases
and controls with the use of the AIB1 Prism 7700 Sequence
Detection System. DNA was extracted from peripheral blood
cells by using salt extraction methods for those recruited
before 1995 [42] and with the use of spin columns (Mini blood
spin columns; Qiagen, Hilden, Germany) for those recruited
from 1995 onwards.
Statistical methods
As one purpose of this study was to try to replicate the effect
modification effects previously reported in the literature that
are consistent with an increased exposure to endogenous
oestrogen associated with genotypes defined by the C (A2)
variant [5,9,11,19,24,35], we categorized risk factorsAvailable online http://breast-cancer-research.com/content/7/4/R513
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collected in our study in an identical manner to the most com-
prehensive study assessing effect modification, the WYNBCS
[5]. As far as possible, analyses were adjusted for the same
factors and the results presented similarly. Consequently,
reproductive variables were categorized as follows: age at
menarche (less than 13 years, 13 years or more); age at first
birth (less than 25 years, 25 years or more); ever use of oral
contraceptives (yes, no); family history of breast cancer (yes,
no for any first-degree relative reported to have had breast
cancer); age at menopause (less than 48 years, 48 years or
more); and ever use of hormone replacement therapy (HRT;
yes, no).
The Hardy–Weinberg equilibrium assumption was assessed
by comparing the genotype frequencies with those expected
on the basis of the observed allele frequencies and random
mating by using the Pearson χ 2 distribution with one degree of
freedom. The associations between risk of breast cancer and
risk factors and CYP17 genotypes were assessed by multiple
linear logistic regression, adjusting for the potential confound-
ers reference age, body mass index, family history, education
level, country of birth, benign breast disease, and age at men-
opause in postmenopausal women. Odds ratios (ORs) and
95% confidence intervals (CIs) were calculated with and with-
out adjustment for measured risk factors. Logistic regression
was also used to assess, in controls, the associations of hor-
mone-related risk factors with genotype after adjusting for the
above potential confounders. The statistical significance of
interaction terms was assessed by the likelihood ratio test. All
analyses were conducted with Stata version 8.0. All statistical
tests were two-sided and the P values quoted are nominal;
that is, no attempt was made to adjust for multiple compari-
sons, either in terms of the number of covariates or in terms of
the number of modes of inheritance being considered.
A visual comparison between the results of the ABCFS and
those of the WNYBCS was conducted by plotting the corre-
sponding log OR estimates from each study against one
another, using R version 1.6.2. The size of the points was pro-
portional to the average of the inverse of standard errors of the
two studies for that particular risk factor's estimate, so that
larger points were those for which there was more precision.
A positive correlation between the data points would be evi-
dence for replication of findings.
Results
Analyses were conducted for the 1,284 cases and 679 con-
trols genotyped for CYP17, including 1,572 premenopausal
women (mean age 38.3 years) and 391 postmenopausal
women (mean age 52.3 years). There was no evidence of devi-
ation from Hardy–Weinberg equilibrium in controls (P = 0.95),
but in cases there was marginally significant evidence of such
deviation, with a deficiency of heterozygotes (565 observed
versus 605.3 expected; P = 0.02). The C (A2) allele frequency
in cases was 0.38 (SEM 0.001) in cases, and 0.37 (SEM
0.01) in controls (P for difference = 0.8).
Table 1 shows that there were no associations between
breast cancer risk and CYP17 genotypes under codominant
inheritance, among either postmenopausal or premenopausal
women, with or without adjusting for covariates. For dominant
inheritance, the adjusted OR estimates were 0.94 (95% CI
0.76 to 1.18) and 1.31 (95% CI 0.84 to 2.05) among premen-
opausal and postmenopausal women, respectively. For reces-
sive inheritance, the adjusted OR estimates were 1.15 (95%
CI 0.85 to 1.56) and 1.12 (95% CI 0.60 to 2.09) among pre-
menopausal and postmenopausal women, respectively. We
also examined risk for women stratified by report of family his-
tory, because our previous examination of a subset of the data
found evidence for increased risk associated with the CC (A2/
A2) genotype among women reporting a first-degree or sec-
ond-degree family history of breast cancer. The OR for the CC
(A2/A2) genotype was 1.10 (95% CI 0.81 to 1.49) for no fam-
ily history and 2.46 (95% CI 0.70 to 8.60) for family history
under a codominant model of inheritance, and 1.13 (95% CI
0.85, 1.50) for no family history and 2.37 (95% CI 0.72, 7.79)
for family history under a recessive model of inheritance.
We excluded the 41 Caucasian cases with a known BRCA1
or BRCA2 germline mutation; because these mutations are
associated with at least a 10-fold increased breast cancer risk
[43], for more than 90% of them the cause of their disease
was their germline mutation (that is, less than 10% are likely to
be phenocopies). It is possible that their CYP17 genotype
could have a modifying effect on their disease risk; however,
the frequencies of the TT (A1/A1), TC (A1/A2) and CC (A2/A2)
genotypes were 41% (n  = 17), 41% (17) and 18% (7),
respectively, in carriers, similar to those of 40% (513), 44%
(565), and 16% (206) observed in the non-carrier cases (P =
0.95). The C (A2) allele frequency was 0.38 in both carriers
and non-carriers.
Table 2 shows the distribution among controls of the CYP17
genotypes defined by the polymorphism, under a dominant
model, in relation to reproductive and hormonally related risk
factors, and family history status based on first-degree rela-
tives, stratified by menopause status. The only significant
association was between age at menarche and CYP17 geno-
type in the premenopausal women (P = 0.002), such that con-
trols with the TT (A1/A1) genotype were more likely to have an
age at menarche of less than 13 years. There was no evidence
that women with a T (A1) allele were more likely to have used
HRT. The strengths of the estimated associations between
genotype and risk factor were little changed by also adjusting
for potential confounders.
Table 3 shows that there was nominally significant evidence
that ever use of HRT was associated with an increased risk of
breast cancer among all women (OR 1.86; 95% CI 1.11 toBreast Cancer Research    Vol 7 No 4    Chang et al.
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3.12; P = 0.02). This effect was significant among women
homozygous for the T (A1) allele (OR 2.40; 95% CI 1.01 to
5.70; P = 0.05), but not significant for women with at least one
C (A2) allele (OR 1.93; 95% CI 0.93 to 4.02; P = 0.08); the
two estimates were not significantly different from one another
(P = 0.7). There was at best marginally significant evidence
that later age at menopause was associated with an increased
breast cancer risk in women homozygous for the T (A1) allele
(OR 2.59; 95% CI 0.97 to 6.95; P = 0.06), but not in women
with at least one C (A2) allele, and the difference in risk esti-
mate by genotype was also not statistically significant (P =
0.06).
We compared the adjusted OR estimates of each risk factor
and breast cancer risk for each CYP17 genotype presented in
Table 3 with those reported in the literature. A visual compari-
son between the results of the ABCFS and those of the WNY-
BCS [5] is shown in Fig. 1. This graphical presentation reveals
no association between the point estimates and therefore no
evidence for consistency in the estimates overall, or that any
one or more findings were strong or statistically significant in
both studies. The most consistent finding was for an increased
risk in postmenopausal women with older age at menopause
and A1/A1 genotype, but evidence was weak in the present
study and not significant in the WNYBCS [5]. Other studies
have examined association between genotype and menopau-
sal status [15] or age at menopause [37], or risk associated
with genotype in subgroups stratified by menopausal status
[12], and none have reported statistically significant findings.
Similarly, we failed to confirm other positive reports of associ-
ations with hormonal risk factors, or of effect modification, as
detailed below.
Discussion
Consistent with most previous studies and a recent meta-anal-
ysis was our failure to find any evidence for an association
between the CYP17 genotype defined by the – 34 promoter
region T→ C nucleotide-substitution polymorphism and risk of
breast cancer overall, or within premenopausal or postmeno-
pausal women, whether the genotype be defined under a
codominant or a recessive mode of inheritance. Specifically,
Table 1
CYP17 genotypes and breast cancer risk by menopausal status (BRCA1 and BRCA2 mutation carriers excluded)
Genotype Cases, n (%) Controls, n (%) Crude OR (95% CI) Adjusted OR (95% CI)a
Premenopausal
A1/A1 (TT) 414 (40) 201 (38) 1.00 1.00
A1/A2 (TC) 460 (44) 253 (48) 0.88 (0.70, 1.11) 0.90 (0.71, 1.14)
A2/A2 (CC) 169 (16) 75 (14) 1.09 (0.79, 1.51) 1.08 (0.78, 1.51)
Postmenopausal
A1/A1 (TT) 99 (41) 66 (44) 1.00 1.00
A1/A2 (TC) 105 (44) 64 (43) 1.09 (0.70, 1.70) 1.32 (0.82, 2.12)
A2/A2 (CC) 37 (15) 20 (13) 1.23 (0.66, 2.31) 1.29 (0.66, 2.52)
Pooled
A1/A1 (TT) 513 (40) 267 (39) 1.00 1.00
A1/A2 (TC) 565 (44) 317 (47) 0.93 (0.76, 1.14) 0.96 (0.77, 1.18)
A2/A2 (CC) 206 (16) 95 (14) 1.13 (0.85, 1.50) 1.12 (0.83, 1.51)
No family historyb
A1/A1 (TT) 462 (40) 249 (39) 1.00 1.00
A1/A2 (TC) 501 (44) 296 (47) 0.91 (0.74, 1.13) 0.95 (0.76, 1.18)
A2/A2 (CC) 182 (16) 91 (14) 1.08 (0.80, 1.45) 1.10 (0.81, 1.49)
With family historyb
A1/A1 (TT) 51 (37) 18 (42) 1.00 1.00
A1/A2 (TC) 64 (46) 21 (49) 1.08 (0.52, 2.23) 1.08 (0.49, 2.36)
A2/A2 (CC) 24 (17) 4 (9) 2.12 (0.65, 6.94) 2.46 (0.70, 8.60)
aOdds ratio (OR) adjusted for reference age, body mass index, family history defined by any first-degree relative who had breast cancer, state, 
education level, country of birth, benign breast lump and age at menopause in postmenopausal women.
bFamily history defined by any first-degree relative who had breast cancer.Available online http://breast-cancer-research.com/content/7/4/R513
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we failed to confirm our own positive finding [23] of a
significantly increased risk associated with the CC (A2/A2)
genotype in women reporting a positive family history.
When we examined associations between CYP17 genotypes
and hormone-related risk factors in controls, the only signifi-
cant finding was an increased risk for older age at menarche
among premenopausal women with the C (A2) allele. This find-
ing is not consistent with previous positive reports, or with the
hypothesis that the C (A2) allele is associated with increased
endogenous oestrogen levels and an earlier age at menarche.
The point estimates for the effects on breast cancer risk of
later age at menopause and HRT use were stronger among
women carrying the TT (A1/A1) genotype, but the interaction
terms were not statistically significant.
Other studies investigating the influence of CYP17 genotype
on hormonal risk factors have found varying results. For exam-
ple, the CYP17  variant was associated with earlier age at
menarche in only two of eight reports
[8,9,13,18,21,27,36,37]. Positive association with early age
at first birth was observed in two of three reports
[5,8,9,11,21], and only single studies have reported signifi-
cant associations with decreased use of HRT [35] and with
decreased difficulty in becoming pregnant [5].
Results from previous studies on the effect modification of
reproductive risk factors by CYP17 genotypes have also been
conflicting. The most consistent association reported was an
effect modification of age at menarche. Four studies have pre-
sented evidence that the protective effect for a later age at
menarche (at least 13 years) was mainly limited to women with
the wild-type homozygous genotype [5,9,11,19], but in two of
these studies the effect was observed only in premenopausal
women [5,19], and seven other studies have failed to confirm
these results [8,12,13,18,21,27,36]. Reports of significant
associations between risk and age at first birth within strata of
CYP17 genotype were in opposing directions from two stud-
ies reporting such results [11,21].
Our larger study found no association between breast cancer
and age at menarche or age at first birth within any of the var-
iant genotypes, either overall or within postmenopausal or pre-
menopausal women. Although we have found at best
marginally significant associations between breast cancer risk
and both HRT use and age at menopausal status within some
CYP17 genotype groups, these must be interpreted with cau-
tion. We considered both premenopausal and postmenopau-
sal women, seven risk factors, and two genotype groups, so by
chance alone we would expect to find a few significant results
even if there were no real effects.
Table 2
Breast cancer risk factors by CYP17 genotype (BRCA1 and BRCA2 mutation carriers excluded)
Factor Premenopausal (n = 529) Postmenopausal (n = 150) Pooled (pre- and postmenopausal) (n = 679)
CYP17 genotype... A1/A1 A1/A2 and A2/A2 A1/A1 A1/A2 and A2/A2 A1/A1 A1/A2 and A2/A2
Age at menarche
<13 years 95 (48) 112 (34)** 28 (42) 35 (42) 123 (46) 147 (36)***
≥ 13 years 105 (52) 216 (66) 38 (58) 49 (58) 143 (54) 265 (64)
Age at first birth
<25 years 52 (37) 93 (40) 37 (61) 40 (54) 89 (44) 133 (43)
≥ 25 years 89 (63) 142 (60) 24 (39) 34 (46) 113 (56) 176 (57)
Ever use oral contraceptives
No 12 (6) 20 (6)
Yes 189 (94) 308 (94)
Family history of breast cancer
No 189 (94) 309 (94) 60 (91) 78 (93) 249 (93) 387 (94)
Yes 12 (6) 19 (6) 6 (9) 6 (7) 18 (7) 25 (6)
Age at menopause
<48 years 40 (61) 45 (54)
≥ 48 years 26 (39) 39 (46)
Ever use HRT
No 28 (42) 33 (48)
Yes 38 (58) 51 (61)
Data are presented as n (%). **P = 0.002, ***P = 0.006. Information on difficulty getting pregnant was unavailable. HRT, hormone 
replacement therapy.Breast Cancer Research    Vol 7 No 4    Chang et al.
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Perhaps more convincing evidence against a role of this
CYP17 variant in modulating endogenous oestrogen levels
and associated breast cancer risk factors is the results of a
recent study of 1,975 postmenopausal women, which found
no association between CYP17 genotypes defined by several
polymorphisms and mean levels of sex hormones, in particular
oestradiol, oestrone and sex-hormone-binding globulin [25].
This suggests that there might be little if any functional effect
of the common CYP17 polymorphisms, at least among post-
menopausal women, although there is a possibility that there
might exist other variants and haplotypes associated with hor-
mone levels and risk of breast cancer.
Although we have conducted a relatively large study, there are
some limitations. Because the functionality, if any, of the poly-
morphism we have studied is not well established, it was not
possible to specify a priori hypotheses about the likely exist-
ence and direction of interactions with risk factors. However,
the few positive associations with serum hormone levels
reported in the literature would suggest that the C (A2) variant
would be associated with increased endogenous hormone
levels, and we have observed significant effects both contra-
dicting and in support of such an association. In addition, in
this and other similar studies, there are multiple tests being
conducted; the quoted P values are only nominal and should
be interpreted accordingly. Consequently, we cannot claim
Table 3
Breast cancer risk and risk factors by CYP17 genotype (BRCA1 and BRCA2 mutation carriers excluded)
Factor All data A1/A1 A1/A2 and A2/A2
Case, n (%) Control, n (%) OR (95% CI) Case, n (%) Control, n (%) OR (95% CI) Case, n (%) Control, n (%) OR (95% CI)
Premenopausal
Age at 
menarche
<13 years 435 (42) 207 (39) 1.00 183 (45) 95 (47) 1.00 252 (40) 112 (34) 1.00
≥ 13 years 603 (58) 321 (61) 0.93 (0.7–1.2) 228 (55) 105 (53) 1.18 (0.8–1.8) 375 (60) 216 (66) 0.79 (0.6–1.1)
Age at first 
birth
<25 years 318 (40) 145 (39) 1.00 131 (42) 52 (37) 1.00 187 (39) 93 (40) 1.00
≥ 25 years 479 (60) 231 (61) 1.13 (0.9–1.5) 183 (58) 89 (63) 0.93 (0.6–1.5) 296 (61) 142 (60) 1.30 (0.9–1.8)
Ever use OC
No 87 (8) 32 (6) 1.00 32 (8) 12 (6) 1.00 55 (9) 20 (6) 1.00
Yes 955 (92) 497 (94) 0.82 (0.5–1.4) 382 (92) 189 (94) 0.75 (0.3–1.9) 573 (91) 308 (94) 0.82 (0.4–1.7)
Postmenopausal
Age at 
menarche
<13 years 101 (42) 63 (42) 1.00 44 (44) 28 (42) 1.00 57 (40) 35 (42) 1.00
≥ 13 years 140 (58) 87 (58) 0.92 (0.6–1.5) 55 (55) 38 (58) 0.83 (0.4–1.9) 85 (60) 49 (58) 0.84 (0.4–1.7)
Age at first 
birth
<25 years 122 (60) 77 (57) 1.00 47 (57) 37 (61) 1.00 75 (62) 40 (54) 1.00
≥ 25 years 79 (40) 58 (43) 0.98 (0.6–1.6) 35 (43) 24 (39) 1.16 (0.5–2.7) 44 (38) 34 (46) 0.84 (0.4–1.7)
Ever use HRT
No 79 (33) 61 (41) 1.00 31 (31) 28 (42) 1.00 45 (32) 33 (39) 1.00
Yes 165 (67) 89 (59) 1.86 (1.1–3.1)1 68 (69) 38 (58) 2.40 (1.0–5.7)2 97 (68) 51 (61) 1.93 (0.9–4.0)3
Age at 
menopause
<48 years 136 (56) 85 (57) 1.00 50 (51) 40 (61) 1.00 83 (58) 45 (37) 1.00
≥ 48 years 107 (44) 65 (43) 1.25 (0.7–2.2) 48 (49) 26 (39) 2.59 (1.0–7.0)4 59 (42) 39 (63) 0.80 (0.4–1.7)
Adjusted odds ratios (ORs) for premenopausal women are adjusted for age at menarche, age at first birth, ever use of OC, reference age, body 
mass index, family history defined by any first-degree relative who had breast cancer, state, education level, country of birth and benign breast lump 
disease. The same adjustment was performed for postmenopausal women except for ever use of hormone replacement therapy (HRT) instead of 
ever use of OC; adjustment was also made for age at menopause. 1P = 0.02, 2P = 0.05, 3P = 0.08, 4P = 0.06.Available online http://breast-cancer-research.com/content/7/4/R513
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with confidence that any of our 'significant' findings represent
true effects. As there seems to be no overall effect of CYP17
genotype on breast cancer risk, finding any true interactions
with breast cancer risk factors (should they exist) will require
massive individual studies, or pooling of studies. The margin-
ally significant deviation from Hardy–Weinberg equilibrium is
unlikely to be due to genotyping error because cases and con-
trols were genotyped at the same time on the same PCR
plates, and thus any genotyping bias (and deviation from
Hardy–Weinberg equilibrium) would be expected to be seen
equally in both cases and controls, but this was not so. Fur-
thermore, our PCR success rate was more than 99.5% for
both cases and controls, and results were fully concordant for
a subset of 168 duplicate DNAs for which PCR was
successful.
The lack of significant associations in our data could be a con-
sequence of not having sufficient statistical power to detect
real effects. In terms of detecting a real effect on breast cancer
risk associated with the homozygote A2/A2 (CC) genotype
(whose frequency in controls is 14%; see Table 1), with the
total sample sizes we studied we would have had 80% power
at the 0.05 level of statistical significance to detect effects
greater than the threshold of 1.5-fold. If analyses were
restricted to postmenopausal women, this detection threshold
would become about twofold, whereas if we were to consider
only women with a family history the threshold would be about
threefold to fourfold. Within the two genotype groups (for
example A1/A1 compared with A1/A2 and A2/A2, which subdi-
vides controls 39:61; see Table 1), the detection thresholds
for effects associated with the risk factors (most of which are
divided about 40:60 into two groups; see Table 3) would be a
minimum of 1.8-fold, and much greater for the smaller
subgroupings.
Our study sample was in general younger than that of the other
studies reporting on possible effect modification by CYP17
genotype. Given that the younger the age at onset of breast
cancer the stronger are the familial effects [41], one might
expect the effects of genetic factors to be more pronounced
in earlier onset disease. We therefore interpret our essentially
null results as further support for the increasing body of evi-
dence suggesting that there are no true associations or effect
modifications, or at most weak ones, associated with this spe-
cific genetic variant of CYP17.
Conclusion
In summary, there are no known data to support a functional
effect of this CYP17 polymorphism, and although lack of a
demonstrated association with serum sex hormones does not
exclude a possible functional effect, it does decrease enthusi-
asm for a possible modifying role of this CYP17 polymorphism
on breast cancer risk. We have found little evidence to support
previous reports of gene–environment interaction, in particular
those of the most comprehensive study assessing relation-
ships between CYP17 genotype and breast cancer hormonal
risk factors [5]. Our post hoc power calculations show that we
cannot exclude small main effects, or modest effects within
subgroups. It is sobering to note that, if the aim of a study is to
detect interactions, the size of the study will have to be at least
four times larger than if attention were confined to detecting
main effects of the same magnitude [44]. Given the concomi-
tant issues of multiple testing, very large studies of tens of
thousands of subjects will be required to evaluate gene-envi-
ronment interactions, should they exist, and these will probably
require the pooling of data from multiple studies (such as has
been done by the Collaborative Group on Hormonal Factors in
Breast Cancer).
Despite early enthusiasm and numerous reports of positive
associations between genotypes, risk factors and breast can-
cer risk from small studies, few of these have held up under fur-
ther scrutiny through being reproduced in larger studies. One
educational example is of the association between breast can-
cer and a protein-truncating variant in CHK2 carried by 2.1%
of women. Even in a study of more than 10,000 cases and
9,000 controls reporting a 2.3-fold increased risk for the
CHK2 mutation and a 1.4-fold increased risk of family history,
no nominally significant interactions were found between
CHK2 genotypes and family history (P = 0.1) [45]. Future
studies evaluating gene–environment interaction and cancer
risk will need to be very large to produce credible evidence.
Figure 1
Log odds ratio estimates versus corresponding estimates from the  Western New York Breast Cancer Study Log odds ratio estimates versus corresponding estimates from the 
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